There are currently 1289 clinical trials in Miami, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Miami, GSK Investigational Site, University of Miami Miller School of Medicine-Sylvester Cancer Center and University of Miami Miller School of Medicine. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
NCT06500273
Recruiting
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: Miami Cancer Institute at Baptist Health, Inc., Miami, Florida
Conditions: Large B-cell Lymphoma
Register for Updates
A Study to Evaluate EDG-7500 in People With Renal Impairment
NCT07034768
Recruiting
The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of kidney function impairment versus participants with normal kidney function. The safety of EDG-7500 in participants with different levels of kidney function impairment will also be evaluated in this study.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/20/2025
Locations: The University of Miami Division of Clinical Pharmacology, Miami, Florida
Conditions: Renal Impairments
Register for Updates
A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy
NCT04015141
Recruiting
The purpose of the study is to evaluate the efficacy of perampanel as measured by the 50 percent (%) responder rate during the maintenance period of the core study for seizure frequency in participants with pediatric epileptic syndrome (Cohort 1) and partial-onset seizures (POS) (Cohort 2).
Gender:
ALL
Ages:
Between 1 month and 18 years
Trial Updated:
06/19/2025
Locations: Nicklaus Children's Hospital, Miami, Florida
Conditions: Pediatric Epileptic Syndrome, Partial-onset Seizures
Register for Updates
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)
NCT04665037
Recruiting
This study aims to estimate the pharmacokinetics (PK) of posaconazole (POS, MK-5592) intravenous (IV) and powder for oral suspension (PFS) formulations in pediatric participants \<2 years of age with invasive fungal infection (IFI).
Gender:
ALL
Ages:
Between 1 day and 2 years
Trial Updated:
06/19/2025
Locations: Nicklaus Children's Hospital ( Site 2109), Miami, Florida
Conditions: Invasive Fungal Infection
Register for Updates
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel
NCT05561127
Recruiting
To determine the safety and efficacy of GIE Medical's ProTractX3™ TTS DCB for the treatment of recurrent benign bowel strictures.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
06/19/2025
Locations: Research Associates of South Florida, Miami, Florida
Conditions: Bowel; Stricture
Register for Updates
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus
NCT05561114
Recruiting
To evaluate the safety and efficacy of the ProTractX3™ DCB for the treatment of benign esophageal strictures.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
06/19/2025
Locations: Research Associates of South Florida, Miami, Florida
Conditions: Esophageal Stricture
Register for Updates
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
NCT06225596
Recruiting
This is a global, multicenter, randomized, open-label study, with an adaptive design. The main objective of the study is to measure the efficacy and safety of BT8009 (zelenectide pevedotin) as monotherapy and in combination with pembrolizumab in participants with locally advanced or metastatic urothelial cancer (UC). The study includes a dose selection phase followed by an adaptive design continuation. The study is comprised of 2 cohorts. Cohort 1 will include participants who have not received... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida +1 locations
Conditions: Metastatic Urothelial Cancer
Register for Updates
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
NCT06750432
Recruiting
This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions of PMN310 in patients with early Alzheimer's disease.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/19/2025
Locations: Finlay Medical Research, Miami, Florida +1 locations
Conditions: Alzheimer Disease, Early Onset
Register for Updates
Concomitant LAAC/AF Ablation (Watchman FLX Pro)
NCT07041125
Recruiting
This sub-study is a prospective/retrospective, non-randomized, observational, comparative cohorts study, embedded in and expanding on the infrastructure of a real-world AF ablation registry DISRUPT-AF (NCT06335082).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: HCA Research Institute- Mercy Hospital, Miami, Florida
Conditions: PFA Ablation and LAAC Procedures
Register for Updates
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
NCT06775379
Recruiting
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
06/18/2025
Locations: PharmaSouth Research, Miami, Florida
Conditions: Major Depressive Disorder
Register for Updates
A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
NCT06789445
Recruiting
Study OpCT-001-101 is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in up to approximately 54 adults with primary photoreceptor (PR) disease. Phase 1 will focus on safety and features a dose-escalation design. Phase 2 is designed to gather additional safety data and assess the effect of OpCT-001 on measures of visual function, functional vision, and anatomic measures of engraftment in diff... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Locations: University of Miami, Bascom Palmer Eye Institute, Miami, Florida
Conditions: Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), Usher Syndrome, Cone-Rod Dystrophy, Inherited Retinal Disease (IRD), Rod-Cone Dystrophy, Rod-Cone Disease, Cone-Rod Disease, Retinal Degeneration
Register for Updates
A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.
NCT06806995
Recruiting
This is a Phase I, Single-Center, Open-Label study evaluating the safety and pharmacokinetics of single doses of ZID-FEP and metronidazole alone or in combination utilizing a 3-period, crossover study design. Thirty eligible male and female healthy adult subjects will participate in the study and receive single doses of (1) ZID-FEP 3g IV (ZID 1 g plus FEP 2 g) administered over 1 hour (h); (2) metronidazole 0.5 g IV alone administered over 1 h; and (3) metronidazole 0.5 g IV over 1 h, followed b... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
06/18/2025
Locations: Advanced Pharma CR, LLC, Miami, Florida
Conditions: PHA1A
Register for Updates